



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/781,340	02/17/2004	Neil S. Cutshall	60117-106	9233
22504	7590	09/06/2007		
DAVIS WRIGHT TREMAINE, LLP 1201 Third Avenue, Suite 2200 SEATTLE, WA 98101-3045			EXAMINER DESAI, RITA J	
			ART UNIT 1625	PAPER NUMBER
			MAIL DATE 09/06/2007	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	Application No. 10/781,340	Applicant(s) CUTSHALL ET AL.	
	Examiner Rita J. Desai	Art Unit 1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 21 June 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1-44 is/are pending in the application.
- 4a) Of the above claim(s) 1-30, 43 and 44 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 31-42 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                  | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

### DETAILED ACTION

Claims 31- 42 are pending.

Claims 1-30, 43 and 44 are withdrawn.

#### **Applicants have not amended the claims to the elected group.**

The restriction and election of group IIIa , claims 31-42 wherein R2 is a H, R3 is an aryl or an aryl-alkylene.

The rejection of claims 31-42 under 35 USC 112 still stands.

The rejection is being repeated below:-

The rejection of the claims under 35 U.S.C. 112 first paragraph scope of enablement still stands.

The examiner is repeating the rejection here.

) The breadth of the claims: The instant claims encompass many compounds from an aromatic carbocyclic moiety to an aromatic carbocyclic moiety having many large electron withdrawing and bulky groups substituted on it to a moiety having many heterocyclic rings. These compounds cover a very wide range of compounds. With R1 being R5 or R5-(C1-C6 heteroalkylene )

2) The nature of the invention: The invention is a (highly) substituted compound that is useful to treat and inhibiting various receptors.

3) The state of the prior art: Applicants own background information on the Chemokine receptors and G-proteins indicate that they are of several types and are found in all the

Art Unit: 1625

various cells and tissues and are of a variety of types. G-protein

-coupled 7TM receptor would still be another type. The inhibiting of the various cellular events or treat the various diseases by these receptors is not an absolute predictability.

The state of the prior art is that it involves screening in vitro and invivo to determine which compounds exhibit the desired pharmacological activities. There is no absolute predictability and no established correlation between in vitro activity and the treatment of various diseases and also the IC 50 values, as the in vitro data is not a reliable predictor of success even in view of the seemingly high level of skill in the art. The existence of these obstacles establishes that the contemporary knowledge in the art would prevent one of ordinary skill in the art from accepting any therapeutic regimen on its face.

Please see article by James Cumming et al Expression and Function of Chemokine Receptors CXCR1 and CXCR2 in Sepsis. The article clearly illustrates the complication of selecting therapeutic targets to reduce inflammation. The study clearly shows the specificity of the receptor and the disease.

4) The level of one of ordinary skill: The ordinary artisan is highly skilled.

5) The level of predictability in the art: It is noted that the pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity. In re Fisher, 427 F. 2d 833, 166 USPQ 18(CCPA 1970) indicates that the more unpredictable an area is, the more specific enablement is necessary in order to satisfy the statute. The level of unpredictability in the art is very high couples with the fact that applicants compounds of formula I has a very wide scope with all the various R1 and R4 groups. For e.g. the compounds which differ by a methyl group also show different properties, for e.g. theophylline

and caffeine. One of them is a bronchodilator and they differ only by a methyl group.

6) The amount of direction provided by the inventor: The inventor provides very little direction in the instant specification. There are no examples with the R being hetero cyclic groups and also there is no data provided to show that these compounds do indeed treat various diseases. The only data provided is of 9 compounds that have an IC50 as given in **table 6** page 67, 68 of the specifications. Even this data is not consistent. The first compound does not show any CCR5 activity.! And the second last does not have any NPY1 and somat activity.!

7) The existence of working examples: The instant specification has only 9 examples with a few assays.

8) The quantity of experimentation needed to make or use the invention based on the content of the disclosure: Since there are no working examples, and since the state of the art clearly indicates that diseases are related to very specific sub type receptors coupled with the fact that drugs have very limited predictability, the amount of experimentation is very high and burdensome and it not clear who the patient in need there of is who would require the antagonizing or inhibiting treatment since the scope of the claim is drawn to any chemokine receptor, inhibition of any chemokine mediated cellular "event", without any indication of which patient population.

Taking the above eight factors into consideration, it is not seen where the instant specification enables the ordinary artisan to make and/or use the instantly claimed invention.

A small scope of compounds according to the invention have been made. The assay test is noted. While these screening test in an enzyme assay provides data in certain inhibiting

activity, it does not provide sufficient operational guidance in an “individual” in pathophysiological environment.

Genetech Inc Vs Nova Nordisk 42 USPQ 2d 1001.

“A patent is not a hunting license. It is not a reward for search but compensation for its successful conclusion and patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable.”

Applicants have provided several references to indicate that their compound do indeed treat any and all the various disorders.

1) applicants have provided only 9 compounds with few assays.

The scope of the compounds is unusually large. The only data provided is of 9 compounds that have an IC<sub>50</sub> as given in **table 6** page 67, 68 of the specifications. Even this data is not consistent. The first compound does not show any CCR5 activity.! And the second last does not have any NPY1 and somat. activity.!

The art is highly unpredictable.

The references provided does not teach that the by antagonizing chemokine, one would be able to treat effectively disorders such as cancer, IBD, reperfusion injury, graft vs. Host diseases.

Applicants claim reads “patient” “in need thereof” and “effective amount” implies that it is treating some diseases. The diseases listed in the specifications has a laundry list.

The specification are enabled for a limited scope of compounds, wherein R1 is a halogen or a SO<sub>2</sub>-alkyl, or SO<sub>2</sub>-alkylaryl, and SO<sub>2</sub>-cycloalkyl and n=0.

Claims 41 reads “ an inflammation “event”. The scope of the event is also not enabled.  
The claim 40 reads compounds “ modulate” the binding of MIP-1Beta to a CCR5 cell receptor.  
As does claim 38 and 39. The claim is not enabled for the term Modulating the binding.  
Modulating means changing. Claim 31 states that it is antagonizing. Modulating would  
inherently mean that it would antagonize or agonize the receptor.

The rejection still stands.

The rejection of claims 31-42 under 35 USC second has been withdrawn as applicants have  
amended the claims.

### ***Conclusion***

Claims 31-42 stand rejected.

**THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time  
policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE  
MONTHS from the mailing date of this action. In the event a first reply is filed within TWO  
MONTHS of the mailing date of this final action and the advisory action is not mailed until after  
the end of the THREE-MONTH shortened statutory period, then the shortened statutory period  
will expire on the date the advisory action is mailed, and any extension fee pursuant to 37  
CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,  
however, will the statutory period for reply expire later than SIX MONTHS from the mailing  
date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rita J. Desai whose telephone number is 571-272-0684. The examiner can normally be reached on Monday - Friday, flex time..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Rita J. Desai  
Primary Examiner  
Art Unit 1625

*RJ Desai*  
*8/31/07*

R.D.  
August 31, 2007